Amphetamine has 51 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. 21 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Furazolidone, Mao Inhibitors, Safinamide Mesylate. Patients taking Amphetamine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 51
- Contraindicated
- 3
- Major
- 21
- Moderate
- 26
Contraindicated (3)
- Amphetamine + Furazolidone— Slows amphetamine metabolism, potentiating its effects and risking hypertensive crisis, neurological toxicity, and malig…
- Amphetamine + Mao Inhibitors— MAOI antidepressants slow amphetamine metabolism, increasing effects on norepinephrine release causing hypertensive cris…
- Amphetamine + Safinamide Mesylate— Sympathomimetic medication; concomitant use is contraindicated due to risk of hypertensive crisis.
Major (21)
- Amphetamine + Alkalinizing Agents— Increase blood levels and potentiate the action of amphetamine. Co-administration should be avoided.
- Amphetamine + Citalopram— Concomitant use increases risk of serotonin syndrome.
- Amphetamine + Citalopram Hydrobromide— Concomitant use increases risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation and…
- Amphetamine + Desipramine— Tricyclic antidepressant causing striking sustained increases in d-amphetamine brain concentration with potentiated card…
- Amphetamine + Desvenlafaxine Succinate— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syn…
- Amphetamine + Escitalopram— Concomitant use increases risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation and…
- Amphetamine + Escitalopram Oxalate— Serotonergic drug that increases risk of serotonin syndrome when combined with escitalopram oxalate.
- Amphetamine + Fluoxetine— Increases risk of serotonin syndrome. Monitor patients for signs and symptoms during treatment initiation and dosage inc…
- Amphetamine + Fluoxetine Hydrochloride— Concomitant use increases risk of serotonin syndrome; monitor for symptoms.
- Amphetamine + Milnacipran Hydrochloride— Concomitant use can result in serotonin syndrome. Careful monitoring advised.
- Amphetamine + Mirtazapine— Concomitant use increases risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation and…
- Amphetamine + Paroxetine— Concomitant use of serotonergic drugs with paroxetine increases risk of serotonin syndrome.
- Amphetamine + Protriptyline— Tricyclic antidepressant causing striking sustained increases in d-amphetamine brain concentration with potentiated card…
- Amphetamine + Quinidine— CYP2D6 inhibitor that increases amphetamine exposure and risk of serotonin syndrome.
- Amphetamine + Ritonavir— CYP2D6 inhibitor that increases amphetamine exposure and risk of serotonin syndrome.
- Amphetamine + Sertraline— Concomitant use increases risk of serotonin syndrome. Monitor patients for signs and symptoms, particularly during initi…
- Amphetamine + Sertraline Hydrochloride— Concomitant use increases risk of serotonin syndrome. Monitor patients for signs and symptoms, particularly during treat…
- Amphetamine + Venlafaxine Hydrochloride— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syn…
- Amphetamine + Ziprasidone— Risk of serotonin syndrome with concomitant therapy with amphetamines.
- Amphetamine + Ziprasidone Hcl— Risk of serotonin syndrome with concomitant serotonergic therapy including amphetamines.
- Amphetamine + Ziprasidone Mesylate— Risk of serotonin syndrome with concomitant serotonergic therapy including amphetamines.
Moderate (26)
- Amphetamine + Acetazolamide— Acetazolamide decreases urinary excretion of amphetamine, potentially enhancing magnitude and duration of effect.
- Amphetamine + Acetazolamide Extended-Release— Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of its effect.
- Amphetamine + Acetazolamide Sodium— Acetazolamide decreases urinary excretion of amphetamine and may enhance magnitude and duration of its effect.
- Amphetamine + Acidifying Agents— Lower blood levels and efficacy of amphetamines. Dose adjustment may be needed based on clinical response.
- Amphetamine + Ammonium Chloride— Urinary acidifying agent that increases ionized amphetamine species, increasing urinary excretion and lowering blood lev…
- Amphetamine + Ascorbic Acid— Ascorbic acid may acidify urine and lower amphetamine serum concentrations by increasing renal excretion. Standard monit…
- Amphetamine + Chlorpromazine— Dopamine antagonist that blocks the effects of amphetamines.
- Amphetamine + Desvenlafaxine— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syn…
- Amphetamine + Desvenlafaxine Er— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syn…
- Amphetamine + Duloxetine— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms during treatment initiation and dose increase…
- Amphetamine + Esketamine Hydrochloride— Concomitant use may increase blood pressure. Closely monitor blood pressure with concomitant use.
- Amphetamine + Glutamic Acid Hcl— Gastrointestinal acidifying agent that lowers amphetamine absorption and blood levels, reducing efficacy.
- Amphetamine + Guanethidine— Gastrointestinal acidifying agent that lowers amphetamine absorption and blood levels, reducing efficacy.
- Amphetamine + Ioflupane I-123— Binds to dopamine transporter with high affinity and may interfere with Ioflupane I-123 imaging results.
- Amphetamine + Levomilnacipran Hydrochloride— Serotonergic drugs that increase risk of serotonin syndrome. Monitor for symptoms and discontinue if serotonin syndrome …
- Amphetamine + Nabilone— Additive hypertension, tachycardia, and possibly cardiotoxicity reported with concurrent use.
- Amphetamine + Paroxetine Hydrochloride— Concomitant use of serotonergic drugs with paroxetine increases the risk of serotonin syndrome. Monitor for symptoms.
- Amphetamine + Paroxetine Hydrochloride Hemihydrate— Caution advised due to potential for serotonin syndrome when coadministered with paroxetine.
- Amphetamine + Promethazine Hydrochloride And Phenylephrine Hydrochloride— Phenylephrine with amphetamines causes synergistic adrenergic response.
- Amphetamine + Reserpine— Gastrointestinal acidifying agent that lowers amphetamine absorption and blood levels, reducing efficacy.
- Amphetamine + Sodium Acid Phosphate— Urinary acidifying agent that increases ionized amphetamine species, increasing urinary excretion and lowering blood lev…
- Amphetamine + Sodium Bicarbonate— Gastrointestinal alkalinizing agent that increases amphetamine absorption and blood levels, potentiating effects.
- Amphetamine + Urinary Alkalinizing Agents— Increase blood levels and potentiate the action of amphetamine. Co-administration should be avoided.
- Amphetamine + Venlafaxine— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and consider discontinuation if serotonin syn…
- Amphetamine + Vilazodone Hydrochloride— Serotonergic drugs that increase risk of serotonin syndrome; monitor patients for signs and symptoms during initiation.
- Amphetamine + Vortioxetine— Serotonergic drugs that increase risk of serotonin syndrome when used with TRINTELLIX. Monitor for serotonin syndrome sy…